Tesamorelin, Ipamorelin
Tesamorelin paired with Ipamorelin targets visceral fat obliteration through Tesamorelin’s specific trunk adipose reduction (1.3kg fat mass loss over 26 weeks) amplified by Ipamorelin’s selective GH release (no appetite/cortisol elevation), creating sustained IGF-1 elevation for metabolic and anabolic benefits without DAC-related prolongation risks. Tesamorelin’s FDA-approved HIV lipodystrophy efficacy translates to general visceral fat targeting, enhanced by Ipamorelin’s clean secretagogue profile.
Route
Subcutaneous injection
Dose range
1 mg
Frequency
Once per day (subcutaneous)
Cycle length
12–26 weeks
Overview
Tesamorelin paired with Ipamorelin targets visceral fat obliteration through Tesamorelin’s specific trunk adipose reduction (1.3kg fat mass loss over 26 weeks) amplified by Ipamorelin’s selective GH release (no appetite/cortisol elevation), creating sustained IGF-1 elevation for metabolic and anabolic benefits without DAC-related prolongation risks. Tesamorelin’s FDA-approved HIV lipodystrophy efficacy translates to general visceral fat targeting, enhanced by Ipamorelin’s clean secretagogue profile.
Users achieve waist reductions, improved insulin sensitivity, and lean preservation with minimal side effects. Twice-daily dosing optimizes fat mobilization cycles. For central obesity resistant to diet/exercise, this duo offers targeted lipolysis with full GH axis support.
Studied benefits
- A popular combination for body recomposition
- Tesamorelin provides potent visceral fat-burning properties, while Ipamorelin ensures a steady, safe, and selective boost in overall Growth Hormone production
- This pairing is often used to improve metabolic health and muscle tone
Reported side effects
- Potential for mild musculoskeletal discomfort (joint or muscle aches) and peripheral edema (slight swelling of hands/feet)
- Generally carries a low risk of the "hunger spikes" associated with other GH secretagogues
Protocol
Dosing Schedule (Subcutaneous)
Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.
Tesamorelin + Ipamorelin (10mg/5mg Blend)
Reconstitute with 2.0 mL bacteriostatic water (Conc: 5 mg/mL Tesa | 2.5 mg/mL Ip).
Target visceral fat reduction (Tesamorelin) while providing additional recovery support (Ipamorelin).
| Phase | Tesa Dose (mg) | Draw at 5 mg/mL | Log |
|---|---|---|---|
| Units (mL) | Weeks 1–2 | 1.0 mg | + Log |
| 500 mcg | 20 units (0.20 mL) | Weeks 3–12 | + Log |
| 2.0 mg | 1,000 mcg | 20 units (0.2 mL) | + Log |
Frequency
Once per day (subcutaneous).
Timing
Evening administration preferred.
Cycle length
12–26 weeks.
Unit calculator
Set your vial and water; the table above updates.
5 mg/mL
10 doses of 1 mg per vial
At the starting dose (1 mg × 7/week for a 12-week cycle) you would use about 84 mg, i.e. 9 × 10 mg vials. Higher phases use proportionally more.
Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.
Context
Lifestyle considerations
Maintain a high-protein, calorie-controlled diet to maximize the potent lipolytic synergy of this GHRH and GHRP combination, which specifically targets visceral adipose tissue (VAT). Incorporate high-intensity interval training (HIIT) and resistance exercise to leverage the substantial growth hormone elevation for improved body composition and metabolic rate. Ensure 7–9 hours of quality sleep to synchronize with the deep-sleep GH peaks that this blend is designed to optimize. Adhere to strict fasting protocols—no food for 2–3 hours before and 30–60 minutes after administration—to prevent insulin spikes from blunting the pituitary gland’s secretory response.
Evidence
Research summaries
The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV
Findings: Muscle density improves 1.5-4.9 Hounsfield units (less intramuscular fat), lean muscle area grows in all trunk muscles (0.6-1.1 cm²), reduced sarcopenia risk, better strength
Researchers from Harvard, Colorado, and Johns Hopkins analyzed muscle scans (CT) from 193 HIV patients who responded to tesamorelin vs. 148 on placebo. They looked at four trunk muscle groups: belly (rectus and oblique), hip (psoas), and lower back (paraspinal). Over 26 weeks, tesamorelin boosted muscle density (less fat inside muscle tissue) across all four groups—biggest gain in the rectus (4.9 HU, p<0.005). Lean muscle area (pure muscle without fat) also rose significantly in all four groups (range 0.64-1.08 cm², p<0.005). The lean gains were about double the total muscle area gains, showing tesamorelin specifically forces out intramuscular lipid and builds clean tissue. Total lean body mass gained +1.9 kg on tesamorelin vs. no change on placebo. These changes occurred alongside VAT (belly fat) loss, but multivariate analysis showed muscle improvements held up even after adjusting for fat loss—meaning tesamorelin talks directly to muscle tissue, not just indirectly through fat reduction. Clinically, studies show that 2-5 HU muscle density improvements correlate with better balance, fewer falls, and stronger grip in elderly—real-world function gains. HIV patients on long-term antiretrovirals often develop muscle wasting (sarcopenia); this study hints tesamorelin + exercise could reverse that.
Read the study ↗Effects of Tesamorelin on Nonalcoholic Fatty Liver Disease in HIV: A Randomized, Double-Blind, Multicenter Trial
Findings: Liver fat reduced 37% (relative), normalize liver-to-water ratio, prevent fibrosis progression, reduce inflammation (CRP drops 4.7 mg/L)
61 HIV-infected adults with fatty livers (hepatic fat fraction ≥5% by MRI) were randomized to tesamorelin or placebo for 12 months. Baseline liver fat was 13.8% on average (range 5-45%). Tesamorelin dropped liver fat by 4.1% absolute (31% of the placebo group saw no change), a relative 37% reduction. Notably, 35% of tesamorelin subjects normalized liver fat to <5% (clinical remission) vs. only 4% on placebo. VAT shrank 35 cm² on tesamorelin vs. no change placebo. Lean body mass rose +1.9 kg (tesamorelin) vs. no change (placebo)—muscle sparing during fat loss. Fibrosis progression (liver scarring) was prevented in 10.5% of tesamorelin patients vs. progressed in 37.5% of placebo—a huge protective effect. C-reactive protein (inflammation marker) fell 4.7 mg/L on tesamorelin but rose on placebo. Glucose and insulin sensitivity did NOT worsen (safety win). Side effects were minor (injection site reactions). Context: Fatty liver disease affects 30-40% of HIV patients despite viral suppression and modern antiretrovirals—a hidden epidemic. Traditional drugs don't work well. Tesamorelin targets the root: visceral fat and hepatic fat accumulation via GH stimulation. The 37% relative fat reduction rivals lifestyle interventions, but took just a daily shot. This is one of the few trials actually reversing liver pathology in HIV lipodystrophy.
Read the study ↗Tesamorelin Improves Fat Quality Independent of Changes in Fat Quantity
Findings: Adipocyte quality improves (denser, smaller, healthier cells), better metabolic function, reduced inflammation per adipocyte, preserved subcutaneous fat
341 HIV patients (193 tesamorelin responders, 148 placebo) underwent CT scans to measure not just fat amount but fat density (Hounsfield units—higher HU = better quality). Over 26 weeks, tesamorelin responders experienced VAT density increase +6.2 HU and SAT density increase +4.0 HU, while placebo saw no change. Critically, even after statistically controlling for fat area reduction, VAT and SAT density gains persisted—meaning tesamorelin improved fat quality independent of fat quantity. Why this matters: fatter adipocytes (lower density on CT) are metaboli
Read the study ↗Identification
Chemistry
- cas
- 218949-48-5
- formula
- C₂₂₁H₃₆₆N₇₂O₆₇S
- molecular weight
- 5135.86–5136 g/mol (free base); approximately 5196 Da reported by some suppliers
- sequence
- -
- biosynthesis
- Synthetic (laboratory-synthesized)
- type
- Non-glycosylated synthetic polypeptide
Keep exploring
Related peptides
5-Amino-1MQ
5-amino-1-methylquinolinium · NNMTi
- Route
- Subcutaneous
- Dose
- 2.5 mg – 5 mg
- Cycle
- 10–20 days (based on a single 50 mg vial)
Adipotide (FTPP)
FTPP · Adipotide
- Route
- Subcutaneous
- Dose
- 5 mcg – 20 mcg
- Cycle
- 21–28 days; monitoring of renal markers is standard
AICAR
Acadesine · AICA-Riboside
- Route
- Subcutaneous
- Dose
- 1 mg – 3 mg
- Cycle
- 8–12 weeks
AOD-9604
AOD 9604 · Tyr-hGH fragment 177-191
- Route
- Subcutaneous
- Dose
- 200 mcg – 500 mcg
- Cycle
- 8–12 weeks